Document is current
Any future updates will be listed below
-
Authors
Rahmati, Vahid https://orcid.org/0000-0002-8969-527X
Graf, Jürgen https://orcid.org/0000-0001-8160-1016
Ceanga, Mihai
Cuevas Rivera, Dario https://orcid.org/0000-0003-0516-5210
Haselmann, Holger https://orcid.org/0000-0003-2050-4655
Liebscher, Sabine https://orcid.org/0000-0001-5633-8981
Prüss, Harald https://orcid.org/0000-0002-8283-7976
Holthoff, Knut https://orcid.org/0000-0002-9182-6056
Kirmse, Knut https://orcid.org/0000-0002-9206-214X
Geis, Christian https://orcid.org/0000-0002-9859-581X
- License Information
-
More Information
Article History
Received: 6 November 2024
Revised: 12 February 2026
Accepted: 16 March 2026
First Online: 31 March 2026
Competing interests
: The authors declare no competing interests.
: a) All methods were performed in accordance with the relevant guidelines and regulations. Animal experiments were performed in accordance with the ARRIVE guidelines for reporting animal research and the experimental protocol was in accordance with European regulations (Directive 2010/63/EU); b) The study was approved by the local animal welfare committee (Thüringer Landesamt für Lebensmittelsicherheit und Verbraucherschutz, 02–059/13 and UKJ-23-002). c) Human monoclonal NMDAR-Ab (#003–102) and Control-Ab (#mGO53) were produced in vitro as previously described [ ]. The use of human monoclonal antibodies has been approved by the Ethics committee of Jena University Hospital (#2019-1415).
